Plain-English translation of NCT07647016 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing Trastuzumab Deruxtecan combined with ivonescimab in patients with a specific type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The trial wants to see how well this medication combination works and how safe it is for people whose cancer has returned or spread after earlier treatments. About 53 patients will be enrolled at a cancer center in Shanghai.
Many people with this type of breast cancer eventually stop responding to standard treatments like CDK4/6 inhibitors. This trial explores whether combining these two medications could help patients whose cancer has progressed despite previous therapy.
You likely qualify if…
You likely don't qualify if…
You would receive the two medications as part of a treatment plan overseen by doctors at Fudan University Shanghai Cancer Center. You would have regular visits for physical exams, blood tests, imaging scans, and quality-of-life surveys to track how you're responding to the treatment and any side effects. The study will also collect samples of your tumor and blood to better understand which patients benefit most from this medication combination.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China